202 related articles for article (PubMed ID: 29876931)
21. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
[TBL] [Abstract][Full Text] [Related]
22. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
[TBL] [Abstract][Full Text] [Related]
23. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
[TBL] [Abstract][Full Text] [Related]
24. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
25. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
Pateliya B; Burade V; Goswami S
Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
27. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
28. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
[TBL] [Abstract][Full Text] [Related]
29. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
30. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
[TBL] [Abstract][Full Text] [Related]
31. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line.
Aydinlik S; Erkisa M; Cevatemre B; Sarimahmut M; Dere E; Ari F; Ulukaya E
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):49-57. PubMed ID: 27842219
[TBL] [Abstract][Full Text] [Related]
32. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Li Y; Ahmed F; Ali S; Philip PA; Kucuk O; Sarkar FH
Cancer Res; 2005 Aug; 65(15):6934-42. PubMed ID: 16061678
[TBL] [Abstract][Full Text] [Related]
34. Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.
Liu HC; Chiang CC; Lin CH; Chen CS; Wei CW; Lin SY; Yiang GT; Yu YL
Int J Med Sci; 2020; 17(8):1015-1022. PubMed ID: 32410830
[TBL] [Abstract][Full Text] [Related]
35. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
36. Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.
Koh DW; Powell DP; Blake SD; Hoffman JL; Hopkins MM; Feng X
Oncol Rep; 2015 Sep; 34(3):1589-98. PubMed ID: 26178079
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
38. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
39. Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo.
Xiang L; Xu X; Zhang S; Cai D; Dai X
Free Radic Biol Med; 2018 Aug; 124():205-213. PubMed ID: 29870749
[TBL] [Abstract][Full Text] [Related]
40. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
